■ INTEGRATE-PAIN, a transatlantic US-European interaction in pain research between the NIH HEAL InitiativeSM and the IMI-PainCare consortium ■
Together, we established INTEGRATE-Pain, the “IMI-NIH Transatlantic Emphasis Group on Research And Translation-to-care Efforts for Pain”. Our objectives are transatlantic knowledge sharing, harmonizing of standards, combination of infrastructures, coordination of data collection to improve the statistical power of data interpretation in future meta-analyses, and joint dissemination.
On August 5th and 6th 2020, INTEGRATE-Pain will have virtual meetings, originally planned as personal appointments during the IASP 2020 World Pain Congress.
The NIH HEAL Initiative:
The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Almost every NIH Institute and Center is accelerating research to address this public health emergency from all angles.
The initiative is funding hundreds of projects nationwide. Researchers are taking a variety of approaches to tackle the opioid epidemic through:
- Understanding, managing, and treating pain
- Improving treatment for opioid misuse and addiction
We are delighted that our proposal for a topical workshop “Development of biomarkers for pain: recent advances from research consortia in Europe, U.S.A. and Japan” has been selected for inclusion in the program of the IASP World congress on Pain.
Together with speakers from the U.S.A. and Japan, we will be talking about the need for biomarkers in pain R&D and clinical practice, ultimately to develop novel approaches and for a paradigm change in pain management.
Recent progress of IMI-PainCare and current pain R&D initiatives in U.S.A. and Japan will be presented in generating a comprehensive set of tools which will expand knowledge about pain targets and pathways.
In addition, we will explain efforts to validate biomarkers which will enable stratification of pain patients to allow more individualized treatments, and discover innovative and objective methods for evaluating the success of pain therapies in real-world clinical practice and in clinical trials (Phase II and III).
Looking forward to meeting you at the congress to discuss and invite you to support and synergize with these initiatives.
For more details see https://iaspworldcongress.pathable.co/meetings/DQEhT9wx5Wt2QXdJJ#/